Innovair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Formoterol is a long‑acting β2‑adrenergic agonist. It binds to β2 receptors on airway smooth muscle, stimulating adenylate cyclase and increasing cyclic AMP. The rise in cyclic AMP leads to relaxation of the smooth muscle, producing sustained bronchodilation that helps keep the airways open.

The prescribed dose of Innovair Nexthaler is individualized by the treating physician based on the patient’s severity of disease, age, and response to therapy. The prescriber determines the number of inhalations per day and any dose adjustments required for optimal control.

Safety data for Innovair Nexthaler in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative treatments when appropriate. If therapy is deemed necessary, it should be used at the lowest effective dose and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Innovair Nexthaler delivers its active ingredients via a dry‑powder Nexthaler device, which provides breath‑actuated dosing without the need for propellants. Compared with metered‑dose inhalers, the dry‑powder system may offer more consistent dose delivery and reduced coordination requirements, while the pharmacologic profile of formoterol and beclometasone is similar to other LABA/ICS combinations.

Innovair Nexthaler should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the device away from moisture, direct sunlight and excessive heat to maintain dose integrity and device functionality.

The patient inhales the medication through the Nexthaler device by taking a steady, deep breath through the mouthpiece. No propellant is required; the inhaler releases a measured dose of dry powder when the patient’s inspiratory flow reaches the required threshold. After each use, the mouthpiece should be closed to protect the dose.

Serious risks include paradoxical bronchospasm, which can worsen breathing, and severe allergic reactions such as anaphylaxis. In rare cases, prolonged high‑dose use may lead to adrenal suppression. Patients should be educated to seek immediate medical attention if they experience sudden breathlessness, swelling, rash, or other signs of a severe reaction.

Innovair Nexthaler is contraindicated in individuals with a known hypersensitivity to formoterol, beclometasone, or any excipients in the formulation. It should also be avoided in patients who have experienced a severe allergic reaction to other inhaled corticosteroids or long‑acting β2‑agonists.